Prestige Consumer Healthcare (PBH) Barclays 18th Annual Global Consumer Staples Conference 2025 summary

Business Overview and Brand Strategy

• Maintains a diversified portfolio of leading consumer healthcare brands across GI, women’s health, eye/ear care, skin care, analgesics, and oral care, treating millions of health occasions annually.

• Delivers over 12 billion eye drops, 650 million throat drops, and 17 million pain relief doses annually, treating over 8 million infections each year.

• Portfolio diversity enables resilience to illness trends and supports consistent performance.

• Value creation pillars include brand investment, strong financials, and capital allocation flexibility.

• Five-year CAGRs: revenue 3.5%, organic growth 2.5%, EPS nearly 9%.

Brand Building and Innovation

• Brand growth is driven by consumer insights, agile marketing, and tailored strategies for each brand.

• E-commerce is a key growth channel, now 16% of sales, with sales quadrupling since FY19 and Amazon as a major partner.

• Innovation includes new product forms, technology, and category expansion, such as Dramamine for kids, Summer’s Eve Whole Body Deodorant, and 2-in-1 convenience kits.

• Marketing investments are shifted dynamically based on supply and market conditions.

• Clinical claims and consumer feedback drive product positioning, e.g., TheraTears’ 12-hour relief.

Financial Performance and Capital Allocation

• Maintains strong gross and EBITDA margins (low 30%), with free cash flow of $242M last year and $245M+ expected this year.

• Net leverage reduced from 4.2x to 2.4x over five years, with $1B+ acquisition capacity and $300M share repurchase authorization.

• $52 million in share repurchases in FY25 and a cash build to support future M&A opportunities.

• Capital allocation priorities include investing in brands, pursuing M&A, share repurchases, and deleveraging.

• International business, especially in Australia, is growing in the mid-teens, with strategic expansion in Asia, Europe, and Latin America.